收费全文 | 1378205篇 |
免费 | 111796篇 |
国内免费 | 24828篇 |
耳鼻咽喉 | 15750篇 |
儿科学 | 38310篇 |
妇产科学 | 32534篇 |
基础医学 | 179446篇 |
口腔科学 | 33829篇 |
临床医学 | 139248篇 |
内科学 | 262727篇 |
皮肤病学 | 28904篇 |
神经病学 | 102869篇 |
特种医学 | 55259篇 |
外国民族医学 | 407篇 |
外科学 | 194430篇 |
综合类 | 81495篇 |
现状与发展 | 75篇 |
一般理论 | 351篇 |
预防医学 | 107486篇 |
眼科学 | 31071篇 |
药学 | 107604篇 |
451篇 | |
中国医学 | 21799篇 |
肿瘤学 | 80784篇 |
2022年 | 14969篇 |
2021年 | 21964篇 |
2020年 | 16898篇 |
2019年 | 17428篇 |
2018年 | 20435篇 |
2017年 | 17923篇 |
2016年 | 18859篇 |
2015年 | 24735篇 |
2014年 | 32523篇 |
2013年 | 38688篇 |
2012年 | 51257篇 |
2011年 | 55969篇 |
2010年 | 36525篇 |
2009年 | 32870篇 |
2008年 | 45631篇 |
2007年 | 47491篇 |
2006年 | 47587篇 |
2005年 | 45890篇 |
2004年 | 39080篇 |
2003年 | 38100篇 |
2002年 | 34812篇 |
2001年 | 59226篇 |
2000年 | 60485篇 |
1999年 | 51663篇 |
1998年 | 17522篇 |
1997年 | 15971篇 |
1996年 | 15907篇 |
1995年 | 15936篇 |
1994年 | 14587篇 |
1993年 | 12893篇 |
1992年 | 39536篇 |
1991年 | 38047篇 |
1990年 | 36406篇 |
1989年 | 34558篇 |
1988年 | 31892篇 |
1987年 | 31288篇 |
1986年 | 29412篇 |
1985年 | 28132篇 |
1984年 | 21202篇 |
1983年 | 17920篇 |
1982年 | 11226篇 |
1979年 | 19027篇 |
1978年 | 13674篇 |
1977年 | 11540篇 |
1976年 | 10546篇 |
1975年 | 10940篇 |
1974年 | 12948篇 |
1973年 | 12395篇 |
1972年 | 11341篇 |
1971年 | 10428篇 |
Aims
To obtain an overview of the management and outcomes of children aged 18 years or younger diagnosed with differentiated thyroid carcinoma of follicular cell origin across the UK, by collecting and analysing data from the limited number of centres treating these patients. This multicentre data might provide a more realistic perspective than single-institution series.Materials and methods
Six centres submitted data extracted from historical records on patients aged 18 years or younger, diagnosed between 1964 and 2017. The univariate and multivariable Cox proportional hazard model was used to identify potential predictors of progression-free survival, using national data as a control.Results
Data on 166 patients were available for analysis. Females (74%) were predominant, and the age ranged from 3 to 19 years at diagnosis, mean 14.1 years. Nodal metastases were present in 51%; 12% had distant metastases. After surgery, 95% received radioactive iodine (39% on more than one occasion) and 4% received external beam radiotherapy. With a median follow-up duration of 5 years, 69% are alive with no evidence of disease; 20% are alive with a raised thyroglobulin level as the only evidence of residual disease; 6% have residual structural disease detectable on imaging; 2% have died, from cerebral metastases.Conclusion
Despite most patients having advanced disease at presentation, outcomes are very good. A national prospective registry should allow systematic collection of good-quality data and may facilitate research to further improve outcomes. 相似文献Background
Pure mucinous breast cancer (PMBC) is a rare pathologic type of breast cancer, the prognostic factors of which have not been clearly defined. This study aimed to analyze the prognostic markers and distribution of 21-gene recurrence score (RS) in patients with PMBC.Patients and Methods
Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, a retrospective analysis of PMBC cases was conducted. Multivariate analyses were used to evaluate the indicators for prognosis and the correlations between RS and traditional clinicopathologic characteristics. Disease was subdivided into 4 molecular phenotypes using estrogen receptor (ER) status and tumor grade.Results
Of the 8048 patients, most had ER-positive and node-negative tumors. Multivariate analysis revealed that molecular phenotype as well as age, race, tumor size, and lymph node status was an independent prognostic factor for patients with PMBC (P < .05). The 5-year breast cancer–specific survival of patients among different phenotypes was significantly different (97.9% for ER-positive and grade I tumor, 96.9% for ER-positive and grade II-III tumor, 96% for ER-negative and grade I tumor, 90.1% for ER-negative and grade II-III tumors, P < .001). The proportions of patients categorized into low, intermediate, and high RS risk group were 64.9%, 31.9%, and 3.2%, respectively. Grade, progesterone receptor status, and age were identified as independent variables associated with RS.Conclusion
PMBC had favorable biological features and relatively good prognosis. Molecular phenotype as well as age, race, tumor size, and lymph node status were independent prognostic markers. Furthermore, age, progesterone receptor status, and grade could independently predict RS. 相似文献- Download : Download high-res image (201KB)
- Download : Download full-size image
The ε4 allele of the APOE gene is thought to increase risk from amnestic mild cognitive impairment (aMCI) to Alzheimer’s disease. Cognitive decline in the condition is increasingly considered to worsen functional disconnections in brain network composed of gray matter and white matter. Nevertheless, Whether APOEε4 targets specific white matter functional connectivity in patients with aMCI remains mostly unexplored, mainly due to the challenges of detecting BOLD signals in white matter. Here, we applied a novel approach to investigate APOEε4-related specific bundles and cortical area alterations in aMCI subjects, in order to characterize white matter-gray matter functional connectivity differences throughout the brain. We analyzed 75 patients with aMCI and 76 demographically matched normal controls. The aMCI APOEε4 carriers showed decreased functional connectivity located at left corticospinal tract, bilateral posterior limb of internal capsule, and right temporopolaris, which was different from the regions of aMCI-related changes. We further found that recognition scores were positively associated with the right temporopolaris in aMCI APOEε4 carriers. Collectively, the data provide new evidence that APOEε4 genotype exerts a negative impact on neural activity in both gray and white matter in aMCI, which potentially contributes to functional disconnection and memory decline. A novel method provides full-scale measuring effect of disease conditions on functional architecture throughout the brain. Trial registration: https://www.ClinicalTrials.gov (Identifier: NCT02225964). Registered January 2014.
相似文献- Download : Download high-res image (415KB)
- Download : Download full-size image